External resources PubMed: Pharmacokinetics and clinical implications of semaglutide NCBI StatPearls: Tirzepatide pharmacology and pharmacokinetics New England Journal of Medicine: Retatrutide phase 2 trial data PMC: Clinical recommendations for managing GLP-1 GI adverse events For researchers committed to mastering their GLP-1 protocols with precision, SeekPeptides provides the most comprehensive resource available
GLP-1 is produced by specialised cells, known as L-cells, which are found predominantly in the lower part of the small intestine and the colon
Nutrition Changes That Support Digestion on GLP-1s Small, Frequent Meals Prioritizing small, frequent meals every few hours for blood sugar balance and steady digestion: Aim for 4-6 smaller meals per day Avoid saving calories and eating large portions later, as this can exacerbate reflux Stop eating at the first sign of fullness (goal is 70-80% fullness level vs 100% or Thanksgiving dinner fullness level) Why it helps: Less stomach distention = less pressure = less reflux Medical Nutrition Therapy (MNT) for GLP-1s Balanced meals with emphasis on protein, eating protein first to avoid getting too full before protein goal is met Getting the right amount of fiber for you to prevent constipation Moderate to low fat, since fat can slow down stomach emptying further Ginger tea or ginger chews for nausea & motility Soft textures during symptom flares may be useful for some (yogurt, cottage cheese, protein shakes, protein pancakes) Hydration Between Meals (Not With) Sip fluids throughout the day Limit large volumes during meals This ensures that digestion is prioritized and the stomach doesnt get overwhelmed with liquid Eating Pace & Posture Eat slowly Stay upright for at least 60-90 minutes after eating Avoid late night meals when possible When the "Burn" Becomes a Red Flag While occasional heartburn is common on GLP-1 therapy, it isnt always a "normal" side effect you should just ignore
Multiple studies demonstrate that proliferation due to incretin mimetics can lead to duct occlusion, promoting the premature release of pancreatic enzymes, thereby triggering acinar cell death 18,26
The unknown ingredient purity and potential contaminants in unregulated products pose unacceptable risks during lactation
